$SNOA

Sonoma Pharmaceuticals, Inc.

CIK:0001367083|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenues	$ 6,406	$ 4,015
Cost of revenues	3,829	2,551
Gross profit	2,577	1,464
Operating expenses:
Research and development	597	594
Selling, general and administrative	2,020	1,965
Total operating expenses	2,617	2,559
Loss from operations	(40)	(1,095)
Other expense, net	(290)	(147)
Loss from operations before income taxes	(330)	(1,242)
Income tax benefit	0	1
Net loss	$ (330)	$ (1,241)
Net loss per share: basic	$ (0.09)	$ (0.76)
Net loss per share: diluted	$ (0.09)	$ (0.76)
Weighted-average shares outstanding: basic	3,846	1,641
Weighted-average shares outstanding: diluted	3,846	1,641
Other comprehensive loss:
Net loss	$ (330)	$ (1,241)
Foreign currency translation adjustments	235	806
Comprehensive loss	$ (95)	$ (435)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (330)	$ (1,241)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	32	36
Stock-based compensation	58	57
Deferred income tax expense	0	93
Operating lease right-of-use asset	40	(448)
Changes in operating assets and liabilities:
Accounts receivable, net	(650)	(216)
Inventories, net	(81)	(652)
Prepaid expenses and other current assets	(364)	(819)
Deferred consideration, net of discount	24	55
Accounts payable	216	1,026
Accrued expenses and other current liabilities	391	(484)
Withholding tax payable	63	104
Operating lease liabilities	(40)	448
Deferred revenue	(8)	(26)
Net cash used in operating activities	(649)	(2,015)
Cash flows from investing activities:
Purchases of property and equipment	(2)	(106)
Net cash used in investing activities	(2)	(106)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering expenses	3,536	0
Proceeds from exercise of employee stock options	0	23
Principal payments on short-term debt	(82)	(81)
Net cash provided by (used in) financing activities	3,454	(58)
Effect of exchange rate on cash and cash equivalents	136	410
Net increase (decrease) in cash and cash equivalents	2,939	(1,769)
Cash and cash equivalents, beginning of period	2,399	5,374
Cash and cash equivalents, end of period	5,338	3,605
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 3	$ 3

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Mar. 31, 2026
Current assets:
Cash and cash equivalents	$ 5,338	$ 2,399
Accounts receivable, net	3,182	2,527
Inventories, net	3,786	3,651
Prepaid expenses and other current assets	3,962	3,523
Total current assets	16,268	12,100
Property and equipment, net	290	310
Operating lease, right of use assets	578	602
Deferred tax asset, net	905	884
Other assets	66	64
Total assets	18,107	13,960
Current liabilities:
Accounts payable	2,191	1,923
Accrued expenses and other current liabilities	2,674	2,252
Deferred revenue	282	284
Short-term debt	140	222
Operating lease liabilities, current portion	160	151
Total current liabilities	5,447	4,832
Withholding tax payable	5,627	5,564
Operating lease liabilities, less current portion	439	469
Total liabilities	11,513	10,865
Commitments and Contingencies (Note 5)
Stockholders’ Equity:
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at June 30, 2026 and March 31, 2026, respectively, no shares issued and outstanding at June 30, 2026 and March 31, 2026	0	0
Common stock, $0.0001 par value; 50,000,000 shares authorized at June 30, 2026 and March 31, 2026, 4,785,801 and 1,799,057 shares issued and outstanding at June 30, 2026 and March 31, 2026, respectively	0	0
Additional paid-in capital	210,913	207,319
Accumulated deficit	(201,311)	(200,981)
Accumulated other comprehensive loss	(3,008)	(3,243)
Total stockholders’ equity	6,594	3,095
Total liabilities and stockholders’ equity	$ 18,107	$ 13,960